Description
Anti-CD19-Anti-CD3 Bispecific Antibody (100 µg) | 100441-2 | Gentaur US, UK & Europe Disrtribition
Category: CAR-T/Antibody
Application: This product is for research use only. It is not suitable for human diagnostic or therapeutic use. The anti-CD19-Anti-CD3-His-Tag can be used as a reference BiTE for studying CD19+ cancer cell-mediated T cell activation, using either primary T cells or reporter cell lines such as Jurkat/NFAT-luc (BPS #60621) or Jurkat/IL2-luc (BPS #60481).
Background: Blinatumomab is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It binds to CD19 on cancer cells (e.g. Raji cells) and CD3 on T cells simultaneously, thus bringing T lymphocytes closer to the cancer cells. The binding event potentiates unstimulated T cells and induces direct cytotoxicity against CD19+ cancer cells
Description: Anti-CD19-Anti-CD3-His-Tag is a purified recombinant human bispecific T cell Engager (BiTE) based on Amgen's Blinatumomab. This BiTE has been tested for specific activity in both ELISA binding assay to CD19-biotin and functional reporter assays using Jurkat/NFAT-luc or Jurkat/IL2-Luc reporter cell lines in the presence of CD19+ Raji cells.
Product Type: Antibody
Shippement Condition: -80°C
